US equities
|
SPCX
$163.69
▲+1.95%
MU
$1,024.17
▼-1.13%
TSLA
$388.05
▲+3.48%
NVDA
$231.37
▲+0.39%
AAPL
$333.84
▼-1.93%
AMD
$614.51
▼-0.99%
SNDK
$1,602.67
▼-0.42%
LITE
$1,119.49
▲+6.76%
SPCX
$163.69
▲+1.95%
MU
$1,024.17
▼-1.13%
TSLA
$388.05
▲+3.48%
NVDA
$231.37
▲+0.39%
AAPL
$333.84
▼-1.93%
AMD
$614.51
▼-0.99%
SNDK
$1,602.67
▼-0.42%
LITE
$1,119.49
▲+6.76%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Pacific Biosciences of California, Inc. - Common Stock
(NQ:
PACB
)
2.255
-0.045 (-1.96%)
Delayed Quote
Updated: 10:51 AM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pacific Biosciences of California, Inc. - Common Stock
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
October 01, 2026
Via
AB Newswire
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
May 19, 2026
From
Blank Bio
Via
Business Wire
Ontario-Based DNAstack Leads Sovereign AI for Genomics and Health with Goal of Making Canadians Healthier and Reducing Strain on our Healthcare System
April 07, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Form Bio and PacBio Announce Collaboration to Launch New Resources Set to Transform AAV Design and Analysis Best Practices
June 27, 2024
Via
ACCESSWIRE
Pacific Biosciences (NASDAQ: PACB) Making Surprising Moves in Friday Session
March 31, 2023
Via
Investor Brand Network
PACB Investors Have Opportunity to Join Pacific Biosciences of California, Inc. Fraud Investigation with the Schall Law Firm
August 02, 2024
From
The Schall Law Firm
Via
Business Wire
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
July 16, 2024
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.
Via
MarketBeat
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
August 07, 2023
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms
From
GeneDx Holdings Corp.; PacBio
Via
GlobeNewswire
Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand
November 11, 2021
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force...
Via
FinancialNewsMedia
